# PeptideScanner evidence objects: Nafarelin

Every published version of the records placed with Nafarelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/nafarelin.json. Selected public evidence only; not medical advice.

- Objects: 28
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00034047-nafarelin-v1"></a>

## ClinicalTrials.gov record NCT00034047

> PeptideScanner retained ClinicalTrials.gov record NCT00034047 at 2026-11-16T01:35:57.709Z. Its registry update date was 2008-01-25, and PeptideScanner's reviewed identity mapping was nafarelin.

- Evidence object: `story:clinicaltrials-gov-nct00034047-nafarelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-01-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00034047-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct00034047-nafarelin-v1
- Content SHA-256: `1540fe1bf5437eab6bc27a11b99a9b4aa8eb47d21b2c5c9c1d146fafb72da52a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00034047 ([`ctg-observation-nct00034047-2008-01-25-366e857e84fe`](#source-ctg-observation-nct00034047-2008-01-25-366e857e84fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00034047 at 2026-11-16T01:35:57.709Z. Its registry update date was 2008-01-25, and PeptideScanner's reviewed identity mapping was nafarelin. ([`ctg-observation-nct00034047-2008-01-25-366e857e84fe`](#source-ctg-observation-nct00034047-2008-01-25-366e857e84fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00034047 at 2026-11-16T01:35:57.709Z. Its registry update date was 2008-01-25, and PeptideScanner's reviewed identity mapping was nafarelin. ([`ctg-observation-nct00034047-2008-01-25-366e857e84fe`](#source-ctg-observation-nct00034047-2008-01-25-366e857e84fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00034047-2008-01-25-366e857e84fe`](#source-ctg-observation-nct00034047-2008-01-25-366e857e84fe))

### Sources

<a id="source-ctg-observation-nct00034047-2008-01-25-366e857e84fe"></a>
- **ClinicalTrials.gov record NCT00034047 · retained source version 2008-01-25:366e857e84fe6622b659d80cf9dff10ff735cb4581d9b12329f3e4e2dac2ae7c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00034047) (`ctg-observation-nct00034047-2008-01-25-366e857e84fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00034047." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct00034047-nafarelin-v1 SHA-256: 1540fe1bf5437eab6bc27a11b99a9b4aa8eb47d21b2c5c9c1d146fafb72da52a.

---

<a id="clinicaltrials-gov-nct02865681-nafarelin-v1"></a>

## ClinicalTrials.gov record NCT02865681

> PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin.

- Evidence object: `story:clinicaltrials-gov-nct02865681-nafarelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-03-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02865681-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct02865681-nafarelin-v1
- Content SHA-256: `2355ab0dfa72739caacfbc8b4f49325568fee9a297ab4186b5b544c8ae0127df`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02865681 ([`ctg-observation-nct02865681-2019-03-19-bb19fc851a4d`](#source-ctg-observation-nct02865681-2019-03-19-bb19fc851a4d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin. ([`ctg-observation-nct02865681-2019-03-19-bb19fc851a4d`](#source-ctg-observation-nct02865681-2019-03-19-bb19fc851a4d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin. ([`ctg-observation-nct02865681-2019-03-19-bb19fc851a4d`](#source-ctg-observation-nct02865681-2019-03-19-bb19fc851a4d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02865681-2019-03-19-bb19fc851a4d`](#source-ctg-observation-nct02865681-2019-03-19-bb19fc851a4d))

### Sources

<a id="source-ctg-observation-nct02865681-2019-03-19-bb19fc851a4d"></a>
- **ClinicalTrials.gov record NCT02865681 · retained source version 2019-03-19:bb19fc851a4dccb615d971940efe6e4c70a51c504630d2642989cd0a62e310e3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02865681) (`ctg-observation-nct02865681-2019-03-19-bb19fc851a4d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02865681." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#clinicaltrials-gov-nct02865681-nafarelin-v1 SHA-256: 2355ab0dfa72739caacfbc8b4f49325568fee9a297ab4186b5b544c8ae0127df.

---

<a id="fda-drugs-nda019886-v1"></a>

## Drugs@FDA application NDA019886

> The official Drugs@FDA dataset lists original submission 1 for NDA 019886 with status AP dated 1990-02-13, and names nafarelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019886:v1`
- Evidence domain: Regulatory
- Date in source: 1990-02-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019886/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#fda-drugs-nda019886-v1
- Content SHA-256: `579d6b1a17863330d09b060d64c2062921df064e58d38199f927b323aab75097`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019886 ([`fda-drugs-nda019886-1990-02-13-a62495ef1876`](#source-fda-drugs-nda019886-1990-02-13-a62495ef1876))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019886 with status AP dated 1990-02-13, and names nafarelin acetate among the application record's active ingredients. ([`fda-drugs-nda019886-1990-02-13-a62495ef1876`](#source-fda-drugs-nda019886-1990-02-13-a62495ef1876))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019886 with status AP dated 1990-02-13, and names nafarelin acetate among the application record's active ingredients. ([`fda-drugs-nda019886-1990-02-13-a62495ef1876`](#source-fda-drugs-nda019886-1990-02-13-a62495ef1876))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019886-1990-02-13-a62495ef1876`](#source-fda-drugs-nda019886-1990-02-13-a62495ef1876))

### Sources

<a id="source-fda-drugs-nda019886-1990-02-13-a62495ef1876"></a>
- **Drugs@FDA application NDA019886 · original submission status AP · 1990-02-13 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019886%22&limit=1) (`fda-drugs-nda019886-1990-02-13-a62495ef1876`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019886." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#fda-drugs-nda019886-v1 SHA-256: 579d6b1a17863330d09b060d64c2062921df064e58d38199f927b323aab75097.

---

<a id="pubmed-pmid-10900582-nafarelin-v1"></a>

## Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature.

> PubMed lists PMID 10900582 in The Journal of reproductive medicine as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2000-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-10900582-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-10900582-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-10900582-nafarelin-v1
- Content SHA-256: `fe4a7e671bccdcde5a47e5d12e498c6c7d3827d1391704f1c28b9bb689ba8d9c`

### Claims and source pins

#### Headline

Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. ([`pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1`](#source-pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1))

#### Summary

PubMed lists PMID 10900582 in The Journal of reproductive medicine as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2000-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1`](#source-pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1))

#### Paragraph 1

PubMed lists PMID 10900582 in The Journal of reproductive medicine as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2000-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1`](#source-pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1`](#source-pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1))

### Sources

<a id="source-pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1"></a>
- **Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. · retained source version 1:2013-11-21:current:1cf7f28c2bd113f737351c46f75d3bd8d031243e78b099ba5ad59395cc03df4f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/10900582/) (`pubmed-observation-pmid-10900582-2013-11-21-1cf7f28c2bd1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-10900582-nafarelin-v1 SHA-256: fe4a7e671bccdcde5a47e5d12e498c6c7d3827d1391704f1c28b9bb689ba8d9c.

---

<a id="pubmed-pmid-11495415-nafarelin-v1"></a>

## Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment.

> PubMed lists PMID 11495415 in Journal of assisted reproduction and genetics as Case Reports, Journal Article, with publication-date metadata of 2001-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11495415-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11495415-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11495415-nafarelin-v1
- Content SHA-256: `389e522598fc5ea0f626e531ec94cd21089a497e62e658a078cbdfad3e395217`

### Claims and source pins

#### Headline

Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment. ([`pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8`](#source-pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8))

#### Summary

PubMed lists PMID 11495415 in Journal of assisted reproduction and genetics as Case Reports, Journal Article, with publication-date metadata of 2001-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8`](#source-pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8))

#### Paragraph 1

PubMed lists PMID 11495415 in Journal of assisted reproduction and genetics as Case Reports, Journal Article, with publication-date metadata of 2001-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8`](#source-pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8`](#source-pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8))

### Sources

<a id="source-pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8"></a>
- **Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment. · retained source version 1:2019-05-15:current:47f2257be1d8cf637cf9471d387a0eedebbef8fa9ccc0a33889323cd976902b9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11495415/) (`pubmed-observation-pmid-11495415-2019-05-15-47f2257be1d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11495415-nafarelin-v1 SHA-256: 389e522598fc5ea0f626e531ec94cd21089a497e62e658a078cbdfad3e395217.

---

<a id="pubmed-pmid-11526758-nafarelin-v1"></a>

## \[Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis\].

> PubMed lists PMID 11526758 in Ginekologia polska as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11526758-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-03-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11526758-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11526758-nafarelin-v1
- Content SHA-256: `00b231c31b46174514333c3dde01605bc336a5cc0971f0789ad8965dd430978a`

### Claims and source pins

#### Headline

\[Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis\]. ([`pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c`](#source-pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c))

#### Summary

PubMed lists PMID 11526758 in Ginekologia polska as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c`](#source-pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c))

#### Paragraph 1

PubMed lists PMID 11526758 in Ginekologia polska as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c`](#source-pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c`](#source-pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c))

### Sources

<a id="source-pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c"></a>
- **\[Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis\]. · retained source version 1:2017-03-03:current:bc60174a294c1639ef907d469458631287e593210d382f3c1d1910a774a5b2db** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11526758/) (`pubmed-observation-pmid-11526758-2017-03-03-bc60174a294c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-11526758-nafarelin-v1 SHA-256: 00b231c31b46174514333c3dde01605bc336a5cc0971f0789ad8965dd430978a.

---

<a id="pubmed-pmid-1531576-nafarelin-v1"></a>

## Nafarelin in the management of endometriosis: quality of life assessment.

> PubMed lists PMID 1531576 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1992-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1531576-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1531576-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1531576-nafarelin-v1
- Content SHA-256: `a8eb4fdea1df1c016c203d38fa7063ce0a82ed3c7ec20c3dacf81b3a2db25b7a`

### Claims and source pins

#### Headline

Nafarelin in the management of endometriosis: quality of life assessment. ([`pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad`](#source-pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad))

#### Summary

PubMed lists PMID 1531576 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1992-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad`](#source-pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad))

#### Paragraph 1

PubMed lists PMID 1531576 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1992-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad`](#source-pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad`](#source-pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad))

### Sources

<a id="source-pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad"></a>
- **Nafarelin in the management of endometriosis: quality of life assessment. · retained source version 1:2019-06-15:current:bc486be1dfadfffbc66783bf47111489a969e538e59b5e07a47022cc861316b6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1531576/) (`pubmed-observation-pmid-1531576-2019-06-15-bc486be1dfad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nafarelin in the management of endometriosis: quality of life assessment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1531576-nafarelin-v1 SHA-256: a8eb4fdea1df1c016c203d38fa7063ce0a82ed3c7ec20c3dacf81b3a2db25b7a.

---

<a id="pubmed-pmid-1533376-nafarelin-v1"></a>

## On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.

> PubMed lists PMID 1533376 in Fertility and sterility as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1533376-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1533376-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1533376-nafarelin-v1
- Content SHA-256: `3acfa84c850cdfb78e693b5f0534579e74ee7f44359b112a4861e4ee1db281b1`

### Claims and source pins

#### Headline

On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. ([`pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e`](#source-pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e))

#### Summary

PubMed lists PMID 1533376 in Fertility and sterility as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e`](#source-pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e))

#### Paragraph 1

PubMed lists PMID 1533376 in Fertility and sterility as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e`](#source-pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e`](#source-pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e))

### Sources

<a id="source-pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e"></a>
- **On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. · retained source version 1:2019-07-07:current:89cca5723c5ea5622d6446d64b717d9246fcfadd780b036af65c1a83730ef105** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1533376/) (`pubmed-observation-pmid-1533376-2019-07-07-89cca5723c5e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1533376-nafarelin-v1 SHA-256: 3acfa84c850cdfb78e693b5f0534579e74ee7f44359b112a4861e4ee1db281b1.

---

<a id="pubmed-pmid-18173008-nafarelin-v1"></a>

## \[Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice\].

> PubMed lists PMID 18173008 in Akusherstvo i ginekologiia as Journal Article, Review, with publication-date metadata of 2007 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18173008-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18173008-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-18173008-nafarelin-v1
- Content SHA-256: `f2911e90db9b6e43b493fa5441fbc3e10cd39fc8b89ea5bccaea9a54b3dd15d2`

### Claims and source pins

#### Headline

\[Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice\]. ([`pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4`](#source-pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4))

#### Summary

PubMed lists PMID 18173008 in Akusherstvo i ginekologiia as Journal Article, Review, with publication-date metadata of 2007 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4`](#source-pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4))

#### Paragraph 1

PubMed lists PMID 18173008 in Akusherstvo i ginekologiia as Journal Article, Review, with publication-date metadata of 2007 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4`](#source-pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4`](#source-pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4))

### Sources

<a id="source-pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4"></a>
- **\[Some possibilities for application of "Pfizer" medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice\]. · retained source version 1:2018-12-01:current:fdd1cd3fe6b4eba2d5b876d8120c34bfc10a0853dd1c8ab4b2c5b5ebd3726978** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18173008/) (`pubmed-observation-pmid-18173008-2018-12-01-fdd1cd3fe6b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Some possibilities for application of 'Pfizer' medicines--Prostin 15m, Prostin E2, Prepidil gel, Dostinex, Synarel--in the obstetrician practice\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-18173008-nafarelin-v1 SHA-256: f2911e90db9b6e43b493fa5441fbc3e10cd39fc8b89ea5bccaea9a54b3dd15d2.

---

<a id="pubmed-pmid-1834049-nafarelin-v1"></a>

## A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.

> PubMed lists PMID 1834049 in The Australian & New Zealand journal of obstetrics & gynaecology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-1834049-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-1834049-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1834049-nafarelin-v1
- Content SHA-256: `39c6303cae08c6168730734ff82dfc5d68177bb464794416ea60f77738d570c6`

### Claims and source pins

#### Headline

A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. ([`pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d`](#source-pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d))

#### Summary

PubMed lists PMID 1834049 in The Australian & New Zealand journal of obstetrics & gynaecology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d`](#source-pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d))

#### Paragraph 1

PubMed lists PMID 1834049 in The Australian & New Zealand journal of obstetrics & gynaecology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d`](#source-pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d`](#source-pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d))

### Sources

<a id="source-pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d"></a>
- **A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. · retained source version 1:2019-08-28:current:b3fcb2395c5d11a581c659d2dc59b6fa3163175df0456d3e6037790d1e69aad1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/1834049/) (`pubmed-observation-pmid-1834049-2019-08-28-b3fcb2395c5d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-1834049-nafarelin-v1 SHA-256: 39c6303cae08c6168730734ff82dfc5d68177bb464794416ea60f77738d570c6.

---

<a id="pubmed-pmid-2028837-nafarelin-v1"></a>

## Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group.

> PubMed lists PMID 2028837 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2028837-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2028837-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2028837-nafarelin-v1
- Content SHA-256: `3f1f8bb87b6d5532f20de72089edb79c904f56b83eb9d0ed02ca548b0fb3b2c9`

### Claims and source pins

#### Headline

Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group. ([`pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5`](#source-pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5))

#### Summary

PubMed lists PMID 2028837 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5`](#source-pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5))

#### Paragraph 1

PubMed lists PMID 2028837 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 1991-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5`](#source-pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5`](#source-pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5))

### Sources

<a id="source-pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5"></a>
- **Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group. · retained source version 1:2007-11-15:current:a618dba7f4f56c87d44108af0e2cbde78f2ab61863e2c224b9a230f7698bfb4a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2028837/) (`pubmed-observation-pmid-2028837-2007-11-15-a618dba7f4f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2028837-nafarelin-v1 SHA-256: 3f1f8bb87b6d5532f20de72089edb79c904f56b83eb9d0ed02ca548b0fb3b2c9.

---

<a id="pubmed-pmid-2137620-nafarelin-v1"></a>

## Nafarelin: a new medical therapy for endometriosis.

> PubMed lists PMID 2137620 in Progress in clinical and biological research as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2137620-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2137620-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137620-nafarelin-v1
- Content SHA-256: `6159988db7bc43e14a802f77db7fdf5ce6e243cd68535e87a6b53217fb058ab9`

### Claims and source pins

#### Headline

Nafarelin: a new medical therapy for endometriosis. ([`pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3`](#source-pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3))

#### Summary

PubMed lists PMID 2137620 in Progress in clinical and biological research as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3`](#source-pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3))

#### Paragraph 1

PubMed lists PMID 2137620 in Progress in clinical and biological research as Clinical Trial, Comparative Study, Journal Article, Multicenter Study, with publication-date metadata of 1990 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3`](#source-pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3`](#source-pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3))

### Sources

<a id="source-pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3"></a>
- **Nafarelin: a new medical therapy for endometriosis. · retained source version 1:2013-11-21:current:4f304961f3a37bdedab3c111d4d6d0669ad422cecbbfab2f4baa40b7a4a0aeac** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2137620/) (`pubmed-observation-pmid-2137620-2013-11-21-4f304961f3a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nafarelin: a new medical therapy for endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137620-nafarelin-v1 SHA-256: 6159988db7bc43e14a802f77db7fdf5ce6e243cd68535e87a6b53217fb058ab9.

---

<a id="pubmed-pmid-2137972-nafarelin-v1"></a>

## Nafarelin in the treatment of pelvic pain caused by endometriosis.

> PubMed lists PMID 2137972 in American journal of obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2137972-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2137972-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137972-nafarelin-v1
- Content SHA-256: `f393a4fc2c59155e5d693b24ee024df9ba0aabb52ee1b6b59cfb6fc2e35720ff`

### Claims and source pins

#### Headline

Nafarelin in the treatment of pelvic pain caused by endometriosis. ([`pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922`](#source-pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922))

#### Summary

PubMed lists PMID 2137972 in American journal of obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922`](#source-pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922))

#### Paragraph 1

PubMed lists PMID 2137972 in American journal of obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922`](#source-pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922`](#source-pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922))

### Sources

<a id="source-pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922"></a>
- **Nafarelin in the treatment of pelvic pain caused by endometriosis. · retained source version 1:2019-06-15:current:b1d909a179223ae6888d695db91143eff01d8708d453d98e096157ad6cba15b6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2137972/) (`pubmed-observation-pmid-2137972-2019-06-15-b1d909a17922`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nafarelin in the treatment of pelvic pain caused by endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137972-nafarelin-v1 SHA-256: f393a4fc2c59155e5d693b24ee024df9ba0aabb52ee1b6b59cfb6fc2e35720ff.

---

<a id="pubmed-pmid-2137975-nafarelin-v1"></a>

## Comparison of the pharmacology of nafarelin and danazol.

> PubMed lists PMID 2137975 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2137975-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2137975-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137975-nafarelin-v1
- Content SHA-256: `bb7d6375253f9fd19f3ec49e63f4e7c112eea9819d062c9c69f19a7f01c3aa31`

### Claims and source pins

#### Headline

Comparison of the pharmacology of nafarelin and danazol. ([`pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e`](#source-pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e))

#### Summary

PubMed lists PMID 2137975 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e`](#source-pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e))

#### Paragraph 1

PubMed lists PMID 2137975 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e`](#source-pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e`](#source-pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e))

### Sources

<a id="source-pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e"></a>
- **Comparison of the pharmacology of nafarelin and danazol. · retained source version 1:2019-06-15:current:874a031cb93e333ac8584fc871681534062f5d7cf6dd90d2f051e3fc41befb78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2137975/) (`pubmed-observation-pmid-2137975-2019-06-15-874a031cb93e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of the pharmacology of nafarelin and danazol." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137975-nafarelin-v1 SHA-256: bb7d6375253f9fd19f3ec49e63f4e7c112eea9819d062c9c69f19a7f01c3aa31.

---

<a id="pubmed-pmid-2137976-nafarelin-v1"></a>

## Nafarelin versus danazol in the treatment of endometriosis.

> PubMed lists PMID 2137976 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2137976-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2137976-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137976-nafarelin-v1
- Content SHA-256: `3706569f52d1d7cfe8d13811cc8b185609b0dcfc8e7b8c67b5e5659278b2d723`

### Claims and source pins

#### Headline

Nafarelin versus danazol in the treatment of endometriosis. ([`pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9`](#source-pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9))

#### Summary

PubMed lists PMID 2137976 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9`](#source-pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9))

#### Paragraph 1

PubMed lists PMID 2137976 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9`](#source-pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9`](#source-pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9))

### Sources

<a id="source-pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9"></a>
- **Nafarelin versus danazol in the treatment of endometriosis. · retained source version 1:2019-06-15:current:2e9ab3d6bad92b9891ba2afa27981d85f0106f6d4309851881c91db1e48e0063** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2137976/) (`pubmed-observation-pmid-2137976-2019-06-15-2e9ab3d6bad9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nafarelin versus danazol in the treatment of endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2137976-nafarelin-v1 SHA-256: 3706569f52d1d7cfe8d13811cc8b185609b0dcfc8e7b8c67b5e5659278b2d723.

---

<a id="pubmed-pmid-2140996-nafarelin-v1"></a>

## A comparison of nafarelin acetate and danazol in the treatment of endometriosis.

> PubMed lists PMID 2140996 in Fertility and sterility as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1990-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2140996-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2140996-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2140996-nafarelin-v1
- Content SHA-256: `ec2e3137c8c1ec6b5319642d9b178cd521e2bf08270b41e359b84f6dfb2bbeda`

### Claims and source pins

#### Headline

A comparison of nafarelin acetate and danazol in the treatment of endometriosis. ([`pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627`](#source-pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627))

#### Summary

PubMed lists PMID 2140996 in Fertility and sterility as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1990-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627`](#source-pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627))

#### Paragraph 1

PubMed lists PMID 2140996 in Fertility and sterility as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1990-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627`](#source-pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627`](#source-pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627))

### Sources

<a id="source-pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627"></a>
- **A comparison of nafarelin acetate and danazol in the treatment of endometriosis. · retained source version 1:2019-07-07:current:8a7463dc7627eb98ba32e4ac169d6dec895010907a520aafc5291ef05277e27b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2140996/) (`pubmed-observation-pmid-2140996-2019-07-07-8a7463dc7627`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A comparison of nafarelin acetate and danazol in the treatment of endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2140996-nafarelin-v1 SHA-256: ec2e3137c8c1ec6b5319642d9b178cd521e2bf08270b41e359b84f6dfb2bbeda.

---

<a id="pubmed-pmid-2533526-nafarelin-v1"></a>

## An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.

> PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2533526-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2533526-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533526-nafarelin-v1
- Content SHA-256: `e867ce7d27fb56ecff84f34c7652b83d56d5762c9af6a96721911353897f5f23`

### Claims and source pins

#### Headline

An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin. ([`pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450`](#source-pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450))

#### Summary

PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450`](#source-pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450))

#### Paragraph 1

PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450`](#source-pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450`](#source-pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450))

### Sources

<a id="source-pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450"></a>
- **An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin. · retained source version 1:2026-11-09:current:1f5c14788450c482de6ce4963578e476b0091cb71aa0ba6c54bf5152d5aeee41** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2533526/) (`pubmed-observation-pmid-2533526-2026-11-09-1f5c14788450`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533526-nafarelin-v1 SHA-256: e867ce7d27fb56ecff84f34c7652b83d56d5762c9af6a96721911353897f5f23.

---

<a id="pubmed-pmid-2533616-nafarelin-v1"></a>

## Role of nafarelin in the management of endometriosis.

> PubMed lists PMID 2533616 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2533616-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2533616-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533616-nafarelin-v1
- Content SHA-256: `39dd14f4ee11e31b228f5a3fe8bfff9a154aa56fb65382354192abc8cc0ce393`

### Claims and source pins

#### Headline

Role of nafarelin in the management of endometriosis. ([`pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0`](#source-pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0))

#### Summary

PubMed lists PMID 2533616 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0`](#source-pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0))

#### Paragraph 1

PubMed lists PMID 2533616 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0`](#source-pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0`](#source-pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0))

### Sources

<a id="source-pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0"></a>
- **Role of nafarelin in the management of endometriosis. · retained source version 1:2013-11-21:current:c152f50ea7e01d5c8ab23cc04c1c57bf3ccd9a451423b47e51fb6fdf2c6c9671** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2533616/) (`pubmed-observation-pmid-2533616-2013-11-21-c152f50ea7e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of nafarelin in the management of endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533616-nafarelin-v1 SHA-256: 39dd14f4ee11e31b228f5a3fe8bfff9a154aa56fb65382354192abc8cc0ce393.

---

<a id="pubmed-pmid-2533617-nafarelin-v1"></a>

## Clinical experience treating endometriosis with nafarelin.

> PubMed lists PMID 2533617 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2533617-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2533617-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533617-nafarelin-v1
- Content SHA-256: `b4a8f35e1016f906d9de20eb939ad461a6c8ab6cdd0709ef07b1bf4841cc0c49`

### Claims and source pins

#### Headline

Clinical experience treating endometriosis with nafarelin. ([`pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0`](#source-pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0))

#### Summary

PubMed lists PMID 2533617 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0`](#source-pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0))

#### Paragraph 1

PubMed lists PMID 2533617 in The Journal of reproductive medicine as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 1989-12 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0`](#source-pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0`](#source-pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0))

### Sources

<a id="source-pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0"></a>
- **Clinical experience treating endometriosis with nafarelin. · retained source version 1:2013-11-21:current:a6f5fa0545d094860ca7524fec4f247795bd87f63420ad3daa4780bb6b72154f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2533617/) (`pubmed-observation-pmid-2533617-2013-11-21-a6f5fa0545d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical experience treating endometriosis with nafarelin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2533617-nafarelin-v1 SHA-256: b4a8f35e1016f906d9de20eb939ad461a6c8ab6cdd0709ef07b1bf4841cc0c49.

---

<a id="pubmed-pmid-2535115-nafarelin-v1"></a>

## Experience in the use of nafarelin for treatment of benign breast disease.

> PubMed lists PMID 2535115 in British journal of clinical practice. Supplement as Clinical Trial, Journal Article, with publication-date metadata of 1989-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2535115-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2535115-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2535115-nafarelin-v1
- Content SHA-256: `210becef3946044082ed95e16e9c91eb80dc8fb9af68bbdb510d4e1aeca5580c`

### Claims and source pins

#### Headline

Experience in the use of nafarelin for treatment of benign breast disease. ([`pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5`](#source-pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5))

#### Summary

PubMed lists PMID 2535115 in British journal of clinical practice. Supplement as Clinical Trial, Journal Article, with publication-date metadata of 1989-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5`](#source-pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5))

#### Paragraph 1

PubMed lists PMID 2535115 in British journal of clinical practice. Supplement as Clinical Trial, Journal Article, with publication-date metadata of 1989-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5`](#source-pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5`](#source-pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5))

### Sources

<a id="source-pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5"></a>
- **Experience in the use of nafarelin for treatment of benign breast disease. · retained source version 1:2013-11-21:current:f19f3fbcbdf5269a60b7a9e69b229fddec90760c27dec9916bec6a2cfd2a19b2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2535115/) (`pubmed-observation-pmid-2535115-2013-11-21-f19f3fbcbdf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Experience in the use of nafarelin for treatment of benign breast disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2535115-nafarelin-v1 SHA-256: 210becef3946044082ed95e16e9c91eb80dc8fb9af68bbdb510d4e1aeca5580c.

---

<a id="pubmed-pmid-2970910-nafarelin-v1"></a>

## Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.

> PubMed lists PMID 2970910 in Clinical pharmacology and therapeutics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1988-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-2970910-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-2970910-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2970910-nafarelin-v1
- Content SHA-256: `834d0165d42d8d867a38068bf0bdc1408a93082cf51446f6419aefeea3f58031`

### Claims and source pins

#### Headline

Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. ([`pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb`](#source-pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb))

#### Summary

PubMed lists PMID 2970910 in Clinical pharmacology and therapeutics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1988-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb`](#source-pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb))

#### Paragraph 1

PubMed lists PMID 2970910 in Clinical pharmacology and therapeutics as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 1988-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb`](#source-pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb`](#source-pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb))

### Sources

<a id="source-pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb"></a>
- **Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. · retained source version 1:2019-05-10:current:5e9cef868ebbcb1e59cd06b650f0b86a4fe10898e4aa56ea5faad38d595e7796** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/2970910/) (`pubmed-observation-pmid-2970910-2019-05-10-5e9cef868ebb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-2970910-nafarelin-v1 SHA-256: 834d0165d42d8d867a38068bf0bdc1408a93082cf51446f6419aefeea3f58031.

---

<a id="pubmed-pmid-7473446-nafarelin-v1"></a>

## Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate.

> PubMed lists PMID 7473446 in The Journal of reproductive medicine as Case Reports, Journal Article, with publication-date metadata of 1995-07 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7473446-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7473446-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7473446-nafarelin-v1
- Content SHA-256: `f43d3052cfe5837e1b8f71c83a7078ff8a41c763ba9aac8698dbec3e26d73b22`

### Claims and source pins

#### Headline

Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate. ([`pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394`](#source-pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394))

#### Summary

PubMed lists PMID 7473446 in The Journal of reproductive medicine as Case Reports, Journal Article, with publication-date metadata of 1995-07 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394`](#source-pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394))

#### Paragraph 1

PubMed lists PMID 7473446 in The Journal of reproductive medicine as Case Reports, Journal Article, with publication-date metadata of 1995-07 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394`](#source-pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394`](#source-pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394))

### Sources

<a id="source-pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394"></a>
- **Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate. · retained source version 1:2016-11-23:current:ec9be430d3942fb1ae7a08cd68cbc40f48a803ebc6d451419f3a761b8d65230a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7473446/) (`pubmed-observation-pmid-7473446-2016-11-23-ec9be430d394`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Endometriosis with a pleural effusion and ascites. Report of a case treated with nafarelin acetate." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7473446-nafarelin-v1 SHA-256: f43d3052cfe5837e1b8f71c83a7078ff8a41c763ba9aac8698dbec3e26d73b22.

---

<a id="pubmed-pmid-7485786-nafarelin-v1"></a>

## \[The use of Synarel (nafarelin acetate--spray) in gynecology\].

> PubMed lists PMID 7485786 in Akusherstvo i ginekologiia as Journal Article, with publication-date metadata of 1994 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-7485786-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-7485786-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7485786-nafarelin-v1
- Content SHA-256: `aad6e03112fa5653787d089690c51695adff9331ea5611305248e10950cd33bf`

### Claims and source pins

#### Headline

\[The use of Synarel (nafarelin acetate--spray) in gynecology\]. ([`pubmed-observation-pmid-7485786-2017-11-16-888553936195`](#source-pubmed-observation-pmid-7485786-2017-11-16-888553936195))

#### Summary

PubMed lists PMID 7485786 in Akusherstvo i ginekologiia as Journal Article, with publication-date metadata of 1994 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7485786-2017-11-16-888553936195`](#source-pubmed-observation-pmid-7485786-2017-11-16-888553936195))

#### Paragraph 1

PubMed lists PMID 7485786 in Akusherstvo i ginekologiia as Journal Article, with publication-date metadata of 1994 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-7485786-2017-11-16-888553936195`](#source-pubmed-observation-pmid-7485786-2017-11-16-888553936195))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-7485786-2017-11-16-888553936195`](#source-pubmed-observation-pmid-7485786-2017-11-16-888553936195))

### Sources

<a id="source-pubmed-observation-pmid-7485786-2017-11-16-888553936195"></a>
- **\[The use of Synarel (nafarelin acetate--spray) in gynecology\]. · retained source version 1:2017-11-16:current:888553936195769cde16bc38fe25ae96fbdcdceee2338ffcf2f86b0e3d0c9811** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/7485786/) (`pubmed-observation-pmid-7485786-2017-11-16-888553936195`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[The use of Synarel (nafarelin acetate--spray) in gynecology\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-7485786-nafarelin-v1 SHA-256: aad6e03112fa5653787d089690c51695adff9331ea5611305248e10950cd33bf.

---

<a id="pubmed-pmid-8569395-nafarelin-v1"></a>

## Severe hyperkalaemia with nafarelin.

> PubMed lists PMID 8569395 in Lancet (London, England) as Case Reports, Letter, with publication-date metadata of 1996-02-03 (day precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8569395-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-06-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8569395-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8569395-nafarelin-v1
- Content SHA-256: `704331c6197d1daa4124bc3745b53b1c67aa7459174bf37de3d3d868bc4a96cd`

### Claims and source pins

#### Headline

Severe hyperkalaemia with nafarelin. ([`pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152`](#source-pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152))

#### Summary

PubMed lists PMID 8569395 in Lancet (London, England) as Case Reports, Letter, with publication-date metadata of 1996-02-03 (day precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152`](#source-pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152))

#### Paragraph 1

PubMed lists PMID 8569395 in Lancet (London, England) as Case Reports, Letter, with publication-date metadata of 1996-02-03 (day precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152`](#source-pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152`](#source-pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152))

### Sources

<a id="source-pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152"></a>
- **Severe hyperkalaemia with nafarelin. · retained source version 1:2019-06-11:current:ef0de86971528dc01a9649d9dad1a8e4330990ad380a284ab1b69b3752ed9bc8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8569395/) (`pubmed-observation-pmid-8569395-2019-06-11-ef0de8697152`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Severe hyperkalaemia with nafarelin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8569395-nafarelin-v1 SHA-256: 704331c6197d1daa4124bc3745b53b1c67aa7459174bf37de3d3d868bc4a96cd.

---

<a id="pubmed-pmid-8860440-nafarelin-v1"></a>

## Iontophoresis of nafarelin across human skin in vitro.

> PubMed lists PMID 8860440 in Pharmaceutical research as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-8860440-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-8860440-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8860440-nafarelin-v1
- Content SHA-256: `a078110b65781576c2031867f0741e3d1cd1844d7083a0c727aa9390a2be675b`

### Claims and source pins

#### Headline

Iontophoresis of nafarelin across human skin in vitro. ([`pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843`](#source-pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843))

#### Summary

PubMed lists PMID 8860440 in Pharmaceutical research as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843`](#source-pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843))

#### Paragraph 1

PubMed lists PMID 8860440 in Pharmaceutical research as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843`](#source-pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843`](#source-pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843))

### Sources

<a id="source-pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843"></a>
- **Iontophoresis of nafarelin across human skin in vitro. · retained source version 1:2019-08-18:current:01d2965e284339f7fea285a78161fa97a5fe4f7e65e3c625100222b4cd6bc266** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/8860440/) (`pubmed-observation-pmid-8860440-2019-08-18-01d2965e2843`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Iontophoresis of nafarelin across human skin in vitro." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-8860440-nafarelin-v1 SHA-256: a078110b65781576c2031867f0741e3d1cd1844d7083a0c727aa9390a2be675b.

---

<a id="pubmed-pmid-9209899-nafarelin-v1"></a>

## A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.

> PubMed lists PMID 9209899 in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9209899-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9209899-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9209899-nafarelin-v1
- Content SHA-256: `4c287e094044258478ff754c474f06c89407437d8f05245b1d3736128a0d5a73`

### Claims and source pins

#### Headline

A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. ([`pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9`](#source-pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9))

#### Summary

PubMed lists PMID 9209899 in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9`](#source-pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9))

#### Paragraph 1

PubMed lists PMID 9209899 in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9`](#source-pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9`](#source-pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9))

### Sources

<a id="source-pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9"></a>
- **A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. · retained source version 1:2019-11-02:current:7f31f79e7aa9eaefa20ddc7790b9211dfe20c60d3328ed01caec0f6c5a16a88b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9209899/) (`pubmed-observation-pmid-9209899-2019-11-02-7f31f79e7aa9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9209899-nafarelin-v1 SHA-256: 4c287e094044258478ff754c474f06c89407437d8f05245b1d3736128a0d5a73.

---

<a id="pubmed-pmid-9389816-nafarelin-v1"></a>

## Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis.

> PubMed lists PMID 9389816 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9389816-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9389816-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9389816-nafarelin-v1
- Content SHA-256: `c145acb1fe493ce3e5bcbd68d44b09a5a5c4c567283ef6d9d3a50b12697494b2`

### Claims and source pins

#### Headline

Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. ([`pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b`](#source-pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b))

#### Summary

PubMed lists PMID 9389816 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b`](#source-pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b))

#### Paragraph 1

PubMed lists PMID 9389816 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b`](#source-pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b`](#source-pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b))

### Sources

<a id="source-pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b"></a>
- **Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. · retained source version 1:2019-07-07:current:e236b6c1cb8b99262cc0f2395fd69712707ca0849560934d81639f7edef5a7c7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9389816/) (`pubmed-observation-pmid-9389816-2019-07-07-e236b6c1cb8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9389816-nafarelin-v1 SHA-256: c145acb1fe493ce3e5bcbd68d44b09a5a5c4c567283ef6d9d3a50b12697494b2.

---

<a id="pubmed-pmid-9720832-nafarelin-v1"></a>

## Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study.

> PubMed lists PMID 9720832 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-9720832-nafarelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-9720832-nafarelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9720832-nafarelin-v1
- Content SHA-256: `fd8f5333e51018312e161e21b6008f43957ffa7e433ca55fbed0cfa98463fbe2`

### Claims and source pins

#### Headline

Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study. ([`pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c`](#source-pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c))

#### Summary

PubMed lists PMID 9720832 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c`](#source-pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c))

#### Paragraph 1

PubMed lists PMID 9720832 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c`](#source-pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c`](#source-pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c))

### Sources

<a id="source-pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c"></a>
- **Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study. · retained source version 1:2019-08-16:current:f8990b395f6cbdbd9499eca44b27582c24e011fdebcee07d50cb27379af35ee2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/9720832/) (`pubmed-observation-pmid-9720832-2019-08-16-f8990b395f6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nafarelin.json#pubmed-pmid-9720832-nafarelin-v1 SHA-256: fd8f5333e51018312e161e21b6008f43957ffa7e433ca55fbed0cfa98463fbe2.

